Integrated Strategies to Prevent Intradialytic Hypotension (The DialHypot Study)

Hypotension During Dialysis Clinical Trial

— DialHypot  

Official title:

Integrated Strategies to Prevent Intradialytic Hypotension: a Prospective Randomized Cross-over Trial in Hypotension-prone Hemodialysis Patients (The DialHypot Study)

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03949088
• Other study ID #: DialHypot
• Status: Not yet recruiting
• Phase: N/A
• Start date: June 1, 2019
• Est. completion date: June 1, 2021

Study information

• Verified date: May 2019
• Source: University of Parma
• Contact: Enrico Fiaccadori, Prof.
• Phone: +390521703336
• Email: enrico.faccadori[@]unipr.it
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The present study is aimed at comparing different strategies of UF profiling, dialysate sodium individualization and sodium profiling (even combining one with the other) and at evaluating the effectiveness of a new UF profile which has an ascending/descending shape. The goal of the study is to provide better dialysis tolerance and lower rates of intradialytic hypotensive events by the application of this UF profile design in combination with a neutral sodium balance.

Description:

This is a prospective, randomized, crossover trial. The study will be performed in 2 phases. Each phase will be divided in several sub-phases (see "4.1 Study phases"). Phase 1 will consist of 9 weeks of treatment (27 HD sessions) for each patient; phase 2 will consist of 11 weeks of treatment (33 HD sessions) for each patient. Each subject will be used as his/her own control. Dry weight, anti-hypertensive medications and dialysis parameters will not be modified during the study phases, except for UF rate and dialysate sodium concentration.

Study phases

1 - First phase: validation of the new UF profile with a standard dialysate sodium concentration

1. run-in: constant Na concentration, constant UF rate - 2 weeks (6 sessions)

2. 2-step descending Na profile, linear descending UF profile - 3 weeks (9 sessions)

3. washout: constant Na concentration, constant UF rate - 1 week (3 sessions)

4. 2-step descending Na profile, ascending/descending UF profile - 3 weeks (9 sessions)

2 - Second phase: combination of UF profiles and individualized dialysate sodium concentration

1. run-in: standard constant Na concentration, constant UF rate - 2 weeks (6 sessions)

2. individualized constant Na concentration, constant UF rate - 2 weeks (6 sessions)

3. individualized 2-step Na profile, linear descending UF profile - 3 weeks (9 sessions)

4. washout: individualized constant Na profile, constant UF rate - 1 week (3 sessions)

5. individualized 2-step Na profile, ascending/descending UF profile - 3 weeks (9 sessions)

In phase 1 patients will be randomly assigned to one of the following sequences:

• (1), (2), (3), (4)

• (1), (4), (3), (2)

In phase 2 patients will be randomly assigned to one of the following sequences:

• (1), (2), (3), (4), (5)

• (1), (2), (5), (4), (3) Patients who will be included in phase 1 will undergo at least a 2-week washout period before entering phase 2. During these 2 weeks dry weight and anti-hypertensive therapy may be re-evaluated and re-assessed.

Dialysis prescription

Every patient will undergo a standard HD with the following prescription:

• blood flow: individualized from 250 to 350 mL/min (this value will be established for each patient at the beginning of the run-in phase on the basis of previous evaluations and maintained unchanged for the whole duration of the study)

• dialysate flow: 500 mL/min

• dialysate composition: HCO3- 34 mmol/L, K+ 3 mmol/L, Ca2+ 1.25 mmol/L, Mg2+ 0.5 mmol/L, Cl- 111.5 mmol/L, acetate 3.0 mmol/L, glucose 1 g/L

• dialysate temperature: 36°C

• HD session duration: 4 hours

• during each dialysis session patients will be allowed to drink an amount of maximum 150 mL of water, tea or coffee and they will be allowed to eat a snack

UF profiles

• "linear descending" UF profile: this profile provides a constantly decreasing UF rate during dialysis, starting at a UF rate 1.33 fold the average UF rate (33,25% of total UF rate)

• "ascending/descending" UF profile: this profile can be divided in 2 different phases. The first one includes 3 ascending steps during the first hour of treatment, each step lasting 20 minutes (during the 1st step UF rate is set at 15% of total UF rate, during 2nd step at 25% of total UF rate, during 3rd step at 35% of total UF rate). During the following 3 hours UF rate is shaped as a linear descending UF profile, with a constantly decreasing UF rate, starting at a UF rate 1.33 fold the average UF rate (33,25% of total UF rate)

Dialysate sodium

1. - First phase

• "standard" concentration: the investigators will consider as "standard" a dialysate sodium concentration of 140 mmol/L, which is the concentration usually prescribed in our dialysis facility

• dialysate sodium profile will be shaped as a descending 2-step ramping, each step consisting of half the total treatment duration (2 hours), with a 6 mmol/L difference between the concentrations defined for each of the two steps. Considering a monocompartimental model with variable dialysate sodium, the profile will be set on the basis of an "equivalent sodium". This value will correspond to the dialysate sodium concentration expected to produce the same diffusive balance that a fixed standard concentration (140 mmol/L) would provide: 144 mmol/L for the first 2 hours, 138 mmol/L for the last 2 hours

2. - Second phase

• "individualized" concentration: for each patient dialysate sodium concentration will be established on the basis of the mean of the sodium plasma values measured through pre-HD sampling during the run-in phase (2 repeated measurements before each HD session, for a total of 12 values for each patient). Plasma values will be obtained through a direct potentiometry analysis. Dialysate sodium concentration will be set at the patient's average plasma sodium concentration

• dialysate sodium profile will be shaped as a descending 2-step ramping, each step consisting of half the total treatment duration (2 hours), with a 6 mmol/L difference between the concentrations set for each of the two steps. Considering a monocompartimental model with variable dialysate sodium, the profile will be set on the basis of an "equivalent sodium". This value will correspond to the dialysate sodium concentration expected to produce the same diffusive balance that a fixed individualized concentration (equal to the patient's average plasma sodium concentration) would provide: "average + 4" mmol/L for the first 2 hours, "average
• 2" mmol/L for the last 2 hours

Definition of "dry weight", "UF volume" and "interdialytic weight gain"

• dry weight will be estimated through standard clinical criteria

• total UF volume (net fluid to be removed) will be calculated before each session as the difference between patient's weight and his/her dry weight. A limit of 12.5 mL/kg/h will be considered as maximal total UF volume

• IDGW will be calculated as the difference between patient's weight at the beginning of dialysis and the weight registered at the end of the previous session UF and IDGW will be respectively corrected for pre-HD weight (UF %) and dry weight (IDWG %), thus obtaining measures that will be more relevant to each specific patient.

Primary outcome and definition of "intradialytic hypotension"

The primary outcome will be the incidence of intradialytic hypotensive episodes. Hypotensive events and symptoms (headache, cramps, nausea and vomiting) will be recorded and analyzed as both number of occurrences and time of occurrence from the beginning of the HD session. IDH will be defined as follows:

• "symptomatic IDH": decrease in SBP ≥ 20 mmHg or in MAP ≥ 10 mmHg associated with symptoms (KDIGO definition)

• "asymptomatic IDH": drop in BP (SBP ≥ 20 mmHg or MAP ≥ 10 mmHg) within a 20 minutes interval, regardless of symptoms

• for patients whose SBP is < 100 mmHg at the beginning of treatment, the investigators will consider as IDH any decrease of SBP ≥ 10%

Interventions in case of hypotensive events

• Trendelenburg position

• temporary stop of UF (10 minutes), then restarted at a UF rate equal to "total UF - 100 mL"

• online infusion of 150 mL of saline solution

• discontinuation of the session

BV monitoring Relative blood volume will be evaluated through the BVM system integrated in the dialysis machine. RBV will be recorded every 10 minutes.

Other outcome measurements

• pre-, intra- (after every hour of treatment) and post-HD plasma sodium levels will be determined by direct potentiometry

• blood pressure and heart rate will be recorded every 20 minutes, or more frequently if needed for clinical necessities, by machine-integrated BPM

• achievement of UF will be considered as:

• achievement of dry weight: % target UFDW = UF vol / (preHD weight - dry weight) x 100

• IDWG removal: % target UFWG = UF vol / IDWG x 100

• "UF failure" will be defined as % target UFDW < 70%

• "session failure" will occur when treatment will have to be discontinued before 75% of the prescribed time (before 3 hours of treatment)

• Kt/V will be estimated through the system integrated in the machine (total body water calculated using Watson's equation)

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 60
• Est. completion date: June 1, 2021
• Est. primary completion date: June 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• written informed consent

• age = 18 years

• thrice weekly HD regimen for more than 6 months

• "hypotension-prone patients": = 3 episodes of IDH in the month preceding the run-in phase of the study

Exclusion Criteria:

• IDWG < 1.4% of dry weight (corresponding to < 1 kg in a 70-kg person)

• twice weekly HD regimen

• residual daily urine output > 300 mL

• active acute disease or hospitalization in the 8 weeks preceding the run-in phase

Related Conditions & MeSH terms

• Dialysis Hypotension
• Hypotension
• Hypotension During Dialysis

Intervention

Other:
• UF and Na profiling
Modulation of UF and dialysate sodium

Locations

Country	Name	City	State
Italy	University of Parma - UO Nefrologia AOU	Parma

Sponsors (1)

Lead Sponsor	Collaborator
University of Parma

Country where clinical trial is conducted

Italy, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Occurrence of intradialytic hypotensive episodes (number of episodes within every HD session and time interval from HD start)	Hypotensive events and symptoms (headache, cramps, nausea and vomiting) will be recorded and analyzed as both number of occurrences and time of occurrence from the beginning of the HD session.; IDH will be defined as follows: "symptomatic IDH": decrease in SBP = 20 mmHg or in MAP = 10 mmHg associated with symptoms (KDIGO definition); "asymptomatic IDH": drop in BP (SBP = 20 mmHg or MAP = 10 mmHg) within a 20 minutes interval, regardless of symptoms; for patients whose SBP is < 100 mmHg at the beginning of treatment, the investigators will consider as IDH any decrease of SBP = 10%	Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)
Secondary	Achievement of UF	achievement of dry weight: % target UFDW = UF vol / (preHD weight - dry weight) x 100; IDWG removal: % target UFWG = UF vol / IDWG x 100; "UF failure" will be defined as % target UFDW < 70% "session failure" will occur when treatment will have to be discontinued before 75% of the prescribed time (before 3 hours of treatment)	Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)
Secondary	Dialysis dose	Kt/V: estimated through the system integrated in the machine (total body water calculated using Watson's equation)	Within each dialysis session from the time of enrolment to the end of each study phase (9-11 weeks)